Chengdu Wiskin Biomedical Technology
Developing mRNA therapeutics and cancer vaccines.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
* | $21.0m | Series A | |
| Total Funding | 000k | ||
Related Content
Chengdu Wiskin Biomedical Technology Co., Ltd., also known as WestGene Biopharma, is a biopharmaceutical company established in July 2021. It was co-founded by Dr. Wei Yuquan, an academician of the Chinese Academy of Sciences, and Dr. Xiangrong Song, a scientist with over a decade of experience in mRNA drug research and development who also serves as the CEO. The company is focused on the research and development of innovative mRNA drugs and vaccines.
WestGene's primary work involves developing a pipeline of over 20 mRNA therapeutic products targeting a range of diseases, including cancer, infectious diseases, obesity, and aging. A key product is WGc-043, an mRNA therapeutic cancer vaccine designed to target Epstein-Barr Virus (EBV)-related cancers. In 2024, WGc-043 received Investigational New Drug (IND) approvals from both the U.S. FDA and China's National Medical Products Administration (NMPA), marking a significant milestone for the company. The vaccine works by stimulating the patient's immune system to produce T-cells and antibodies to fight cancer cells and has shown promising safety and efficacy in investigator-initiated trials for nasopharyngeal carcinoma and NK/T-cell lymphoma.
The company's business model appears to be centered on the research, development, and future commercialization of its drug pipeline. WestGene is open to various forms of commercial collaboration, including pipeline licensing, co-development, and technology licensing. WestGene has secured significant funding, including a Series A round of $41.8 million in 2023, to support clinical trials and further research. The company has established five key R&D platforms, including platforms for cancer therapy vaccines, protein replacement drugs, gene editing technology, and preventive vaccines, and has developed a patented LNP delivery system for its mRNA products.
Keywords: mRNA therapeutics, cancer vaccines, Epstein-Barr Virus, oncology, biopharmaceutical, LNP delivery system, clinical trials, drug development, immunotherapy, gene editing